drugset / Trial / NCT00147121

Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)

NCT00147121

RandomizedParallel-groupOpen-labelTreatment

Summary

To establish standard therapy for patients with advanced-stage low grade B-cell lymphoma

Timeline

Start
2002-09
Primary completion
2010-02
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cyclophosphamide Other / unclassified 750 mg/m2 Intravenous
Comparator Doxorubicin Other / unclassified 50 mg/m2 Intravenous
Comparator Prednisone Other / unclassified 100 mg Oral
Comparator Rituximab Monoclonal antibody 375 mg/m2
Comparator Vincristine Small molecule 1.4 mg/m2 Intravenous